Skip to main content

Drug Interactions between Tascenso ODT and teriflunomide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fingolimod teriflunomide

Applies to: Tascenso ODT (fingolimod) and teriflunomide

Talk to your doctor before using fingolimod together with teriflunomide. Combining these medications can increase the risk of serious infections. Rarely, these medications may also cause liver damage. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Because these drugs can stay in your blood for prolonged periods after the last dose (up to 2 months for fingolimod and 2 years for teriflunomide), interactions can occur even if you have stopped taking one medication and are starting the other. Contact your doctor immediately if you develop fever or other signs of infection during treatment with these medications, whether together or alone. You should also seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark-colored urine, light-colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Immunomodulators for multiple sclerosis

Therapeutic duplication

The recommended maximum number of medicines in the 'immunomodulators for multiple sclerosis' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'immunomodulators for multiple sclerosis' category:

  • Tascenso ODT (fingolimod)
  • teriflunomide

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer